U.S. Food and Drug Administration approves Pfizer’s INLYTA® (axitinib)
27 January 2012 | By Pfizer
First treatment to demonstrate superior benefit in a Phase 3 study compared with another targeted agent in advanced RCC...
List view / Grid view
News
GSK announces changes to the Board
27 January 2012 | By GlaxoSmithKline
GlaxoSmithKline plc announced that Sir Crispin Davis, Sir Robert Wilson and Mr Larry Culp will not stand for re-election to the Board...
Boehringer Ingelheim Moves into Phase III for its Head and Neck Cancer Trial Programme for Afatinib*
26 January 2012 | By Boehringer Ingelheim
Boehringer Ingelheim announced the initiation of two phase III clinical trials...
Syrris custom reactors – built for you
26 January 2012 | By Syrris
Syrris Custom Reactor Systems are ideally suited to processes requiring large reactor vessels...
Roche responds to adoption of shareholder rights plan by Illumina Board of Directors
26 January 2012 | By Roche
Roche has responded to an announcement from Illumina, Inc...
ASCEND study to evaluate the effectiveness of TYSABRI® (natalizumab) as a treatment for SPMS
26 January 2012 | By Biogen Idec
Biogen Idec and Elan Corporation, plc announced a global Phase 3b study, ASCEND, that is being conducted to evaluate the effectiveness of TYSABRI as a treatment for SPMS...
Amgen to acquire Micromet
26 January 2012 | By Amgen
Amgen and Micromet, Inc. announced that the companies have entered into a definitive merger agreement...
Boehringer Ingelheim launches ‘Lean-to-Clinic’ program for fast drug product supply
26 January 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has expanded its biopharmaceutical cell line development services...
Antonella Mancuso appointed Patheon’s President, Global Commercial Operations and Chief Manufacturing Officer
Patheon (TSX: PTI) a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that Antonella Mancuso has been promoted to President, Global Commercial Operations and Chief Manufacturing Officer, responsible for Patheon's global commercial manufacturing operations . Ms. Mancuso will assume responsibility for all of…
New FDA approved labeling for VYTORIN® (Ezetimibe/Simvastatin)
25 January 2012 | By Merck
The FDA has approved an updated label for VYTORIN® (ezetimibe/simvastatin)...
Roche offers to acquire all outstanding shares of Illumina, Inc. to further strengthen its leading role in diagnostics
25 January 2012 | By Roche
Roche announced that it is proposing to acquire all outstanding shares of Illumina, Inc...
Genzyme announces FDA approval of Framingham manufacturing plant
24 January 2012 | By Sanofi
The FDA has approved its manufacturing plant in Framingham, Mass., for the production of Fabrazyme® (agalsidase beta)...
Elanco Animal Health announces Lilly’s agreement to acquire ChemGen Corp.
24 January 2012 | By Eli Lilly and Company
Elanco, announced that Lilly has signed an agreement to acquire ChemGen Corp., a privately held bioscience company...
Novo Nordisk establishes type 1 diabetes R&D center in Seattle
24 January 2012 | By Novo Nordisk
Novo Nordisk announced that the company will establish a type 1 diabetes R&D center in Seattle, US...
Bristol-Myers Squibb names Gerald L. Storch to Board of Directors
24 January 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced that its Board of Directors has elected Gerald L. Storch to the Board...
